MTVA News

MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

MetaVia Inc. Announces 1-for-11 Reverse Stock Split

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025